Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The serotonin 1F receptor (5-HT1F, HTR1F) is a G protein-coupled receptor that binds serotonin. It is expressed in the central nervous system, particularly in the cortex, hippocampus, and trigeminal ganglia, as well as in some peripheral tissues. Its primary function involves modulation of neuronal activity and inhibition of trigeminal impulses implicated in migraine pain transmission. Unlike other serotonin receptor subtypes, activation of the serotonin ₁𝐹 receptor does not cause vasoconstriction, making it a target for migraine therapies without cardiovascular side effects. Lasmiditan is a selective agonist approved for the acute treatment of migraine.
Selective activation of the serotonin ₁𝐹 receptor inhibits pain pathways without causing blood vessel constriction.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serotonin 1F Receptor (5-HT1F).